Brussels, 06/07/2011 (Agence Europe) - Settlements that are potentially problematic in terms of anti-trust rules and abuse of dominant position - especially those aimed at delaying or restricting the entry of generic medicines to the market against payment from the originator to the generic company - continue to decrease in importance and number, the European Commission was pleased to state on Wednesday 6 July, in the light of the results of the second series of monitoring exercises on...